This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-04 and is reviewed periodically as new material appears.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Political developments in the Soviet Union included Stalin dismantling the remaining elements of democracy from the party by extending his control over its institutions and eliminating any possible rivals. The party's ranks grew in numbers, with the party modifying its organisation to include more trade unions and factories. The ranks and files of the party were populated with members from the trade unions and the factories, whom Stalin controlled because there were no other Old Bolsheviks to contradict Marxism–Leninism. In the late 1930s, the Soviet Union adopted the 1936 Soviet Constitution which ended weighted-voting preferences for workers, promulgated universal suffrage for every man and woman older than 18 years of age and organised the soviets (councils of workers) into two legislatures, namely the Soviet of the Union (representing electoral districts) and the Soviet of Nationalities (representing the ethnic groups of the country). By 1939, with the exception of Stalin himself, none of the original Bolsheviks of the October Revolution of 1917 remained in the party. Unquestioning loyalty to Stalin was expected by the regime of all citizens. Stalin exercised extensive personal control over the party and unleashed an unprecedented level of violence to eliminate any potential threat to his regime. While Stalin exercised major control over political initiatives, their implementation was in the control of localities, often with local leaders interpreting the policies in a way that served themselves best.
== In nature == Numerous biomolecules exhibit the ability to dissolve certain metal cations. Thus, proteins, polysaccharides, and polynucleic acids are excellent polydentate ligands for many metal ions. Organic compounds such as the amino acids glutamic acid and histidine, organic diacids such as malate, and polypeptides such as phytochelatin are also typical chelators. In addition to these adventitious chelators, several biomolecules are specifically produced to bind certain metals (see next section). Virtually all metalloenzymes feature metals that are chelated, usually to peptides or cofactors and prosthetic groups. Such chelating agents include the porphyrin rings in hemoglobin and chlorophyll. Many microbial species produce water-soluble pigments that serve as chelating agents, termed siderophores. For example, species of Pseudomonas are known to secrete pyochelin and pyoverdine that bind iron. Enterobactin, produced by E. coli, is the strongest chelating agent known. The marine mussels use metal chelation, especially Fe3+ chelation with the Dopa residues in mussel foot protein-1 to improve the strength of the threads that they use to secure themselves to surfaces. In earth science, chemical weathering is attributed to organic chelating agents (e.g., peptides and sugars) that extract metal ions from minerals and rocks. Most metal complexes in the environment and in nature are bound in some form of chelate ring (e.g., with a humic acid or a protein).
By the 20th century, natural pigments gave way to synthetic ones. The invention of phthalocyanine and derivatives of quinacridone, expanded the range of primary blues and reds, getting closer to the ideal subtractive colors and the CMY and CMYK models.
== ST == st – (s) Sotho language (ISO 639-1 code) ST (s) Saint Lucia (FIPS 10-4 country code) São Tomé and Príncipe (ISO 3166 digram) STA (i) Scheduled Time of Arrival Surveillance and Target Acquisition STAGE – (a) Scenario Toolkit And Generation Environment STANAG – (p) (NATO) Standardisation Agreement STAR (a) Scientific and Technical Aerospace Reports (NASA) Simulation of Tactical Alternative Responses Special Threat Analysis and Recognition STAT (a) Signal Transducers and Activators of Transcription (cell biology) Special Tertiary Admissions Test (Australia) STB - Surface Transportation Board STC – (i) Superior Temporal Cortex S&TCD – (i) CERDEC Space and Terrestrial Communications Directorate STD (s) São Tomé and Príncipe dobra (ISO 4217 currency code) (i) Sexually Transmitted Disease STDM – (i) Statistical Time Division Multiplexing STEM (a) Scanning transmission electron microscopy Science, technology, engineering, and mathematics (p) Spatiaotemporal Epidemiological Modeler (IBM-developed software) STENTOR – (p) Satellite de télécommunications pour expérimenter de nouvelles technologies en orbite (French, "Orbital New Technology Experimental Telecommunications Satellite") STFU (i) Southern Tenant Farmers Union Stuff You "Shut the fuck up!" STH – Sonic the Hedgehog STI (i) Sexually Transmitted Infection Subaru Tecnica International STK – (i) Satellite Tool Kit STM – (i) Short Term Memory STOL – (i) Short Take-Off and Landing STOVL – (i) Short Take-Off and Vertical Landing STP (s) São Tomé and Príncipe (ISO 3166 trigram) (i) Standard Temperature and Pressure STR – (i) Short Tandem Repeat (DNA analysis) STRATCOM – (p) United States Strategic Command STRICOM (p) U.S. Army Simulation, Training & Instrumentation Command (1992–) Strike Command (1962–1971) STRIVE – (a) Synthetic Tactical Real-time Interactive Virtual Environment STSM – (i) Senior Technical Staff Member Stuka – (p) Sturzkampfflugzeug (German WWII dive bomber)
Len Butt (1910–1994), footballer, who played over 370 games, including 150 for Macclesfield Town Sir Alex Ferguson (born 1941), former footballer who played 317 league games and manager of Manchester United for 26 years Chris Nicholl (1946–2024), footballer who played 706 games Terry Nicholl (born 1952 in Wilmslow), footballer, played over 450 games Andy Fanshawe (1963–1992), a British mountaineer, attended Wilmslow Grammar School Liz Blatchford (born 1980 in Wilmslow), professional triathlete Danny Whitaker (born 1980 in Wilmslow), footballer, played 671 games, including 400 for Macclesfield Town Park Ji-sung (born 1981), footballer, played 318 games and 134 league games for Manchester United David Horsey (born 1985), golfer who currently plays on the European Tour, lives in Wilmslow Seren Bundy-Davies (born 1994), track and field sprinter at 400 metres, attended Wilmslow High School Sam James (born 1994 in Wilmslow), rugby union player who has played over 250 games; currently with Sale Sharks Millie Turner (born 1996 in Wilmslow), football defender, who has played 180 games for Women's Super League club Manchester United
Sources: en.wikipedia.org
=== August === August 1 A mass shooting occurs at an In-N-Out in Twin Falls, Idaho, leaving four dead (including the perpetrator) and seven injured. The Marine Corps reports that an F-35B stealth warplane crashed in California, but the pilot bailed safely. Cyberwarfare during the Iran war: The New York Times reports, citing state and local officials, that evidence leads to Iran in a series of cyberattacks against water systems in at least seven US states, with Michigan being the second state to report the attacks publicly. August 2 – 2026 Iran war: Following Qatari diplomatic efforts to avert planned strikes and reopen the Strait of Hormuz, and concerns raised by Saudi Crown Prince Mohammed bin Salman over the proposed operation, Trump says that the United States and Israel have called off an attack on Iran after Tehran requested additional time to reach an agreement. Trump nevertheless stresses that the United States remains prepared to launch a large-scale bombing campaign against Iran. August 3 – The Supreme Court declines to halt a $655 million judgement against Palestinian authorities for attacks that killed and maimed Americans in Israel from 2002 to 2004. August 4 – The Women's National Basketball Association (WNBA) announces that the expansion team in Cleveland, Ohio, will be called the Sirens. The organization will debut in 2028. August 5 Drive-thru chain Salad and Go files for Chapter 11 bankruptcy and closes all 70 of its locations across Arizona and Nevada, citing the 2026 cyclosporiasis outbreak as part of the reason for declining business.
"Genius" – 3:43 "Half-Life" – 3:59 "Start Again" (Gerry Leonard) – 3:55 "On Her Mind" (Duncan Sheik, Mick Jones) – 4:11 "Such Reveries" – 5:00 "On a High" – 3:36 "Magazines" – 3:47 "For You" – 2:11 "Good Morning!" – 4:04 "Memento" – 3:47 "Shine Inside" – 10:19 Note: The American version of the album features the song "Chimera" after "Shine Inside" as part of the final track (6 minutes and 28 seconds into the track).
The efficacy of dapagliflozin to improve kidney outcomes and reduce cardiovascular death in people with chronic kidney disease was evaluated in a multicenter, double-blind study of 4,304 participants. In February 2023, the EU authorized dapagliflozin for extended use to cover heart failure patients across the full spectrum of left ventricular ejection fraction (LVEF), including those with mildly reduced and preserved ejection fraction.
Peptidoglycan (PG) is a mesh-like structure containing polysaccharides cross-linked by peptide chains. Penicillin-binding proteins (DD-transpeptidases), in short PBPs, recognize the PG peptides and catalyze the cross-linking reactions. These enzymes are reported to have high specificity toward the chirality center of the amino acid backbone (D-chiral center) but relatively low specificity toward the side-chain structure. Therefore, when FDAAs are present, they are taken by PBPs for the cross-linking reactions, resulting in their incorporation into the PG peptide chains. At proper concentration, e.g. 1–2 mM, FDAAs labeling does not affect PG synthesis and cell growth because only 1%–2% of PG peptide chains are labeled with FDAA.
nj are the stoichiometric coefficients of the reactants in the equilibrium equation, and mj are the coefficients of the products. The value of δGr for these reactions is a function of the chemical potentials of all the species.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.